A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

PHASE4CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

March 5, 2019

Study Completion Date

June 28, 2019

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Fingolimod

Commercially available 0.5mg hard capsules, taken orally once per day

Trial Locations (66)

11772

Novartis Investigative Site, Patchogue

11803

Novartis Investigative Site, Plainview

19140

Novartis Investigative Site, Philadelphia

21093

Novartis Investigative Site, Lutherville

22043

Novartis Investigative Site, Falls Church

22182

Novartis Investigative Site, Vienna

25701

Novartis Investigative Site, Huntington

27103

Novartis Investigative Site, Winston-Salem

27607

Novartis Investigative Site, Raleigh

28117

Novartis Investigative Site, Mooresville

28207

Novartis Investigative Site, Charlotte

28806

Novartis Investigative Site, Asheville

29464

Novartis Investigative Site, Mt. Pleasant

29650

Novartis Investigative Site, Greer

29935

Novartis Investigative Site, Port Royal

30024

Novartis Investigative Site, Suwanee

31406

Novartis Investigative Site, Savannah

32209

Novartis Investigative Site, Jacksonville

32960

Novartis Investigative Site, Vero Beach

33136

Novartis Investigative Site, Miami

33351

Novartis Investigative Site, Sunrise

33482

Novartis Investigative Site, Boca Raton

33487

Novartis Investigative Site, Boca Raton

33952

Novartis Investigative Site, Port Charlotte

34243

Novartis Investigative Site, Sarasota

34471

Novartis Investigative Site, Ocala

35058

Novartis Investigative Site, Cullman

35209

Novartis Investigative Site, Birmingham

37215

Novartis Investigative Site, Nashville

37922

Novartis Investigative Site, Knoxville

40202

Novartis Investigative Site, Louisville

40207

Novartis Investigative Site, Louisville

43081

Novartis Investigative Site, Westerville

43623

Novartis Investigative Site, Toledo

44195

Novartis Investigative Site, Cleveland

45408

Novartis Investigative Site, Dayton

48109

Novartis Investigative Site, Ann Arbor

48867

Novartis Investigative Site, Owosso

53215

Novartis Investigative Site, Milwaukee

54311

Novartis Investigative Site, Green Bay

54956

Novartis Investigative Site, Neenah

55422

Novartis Investigative Site, Golden Valley

60422

Novartis Investigative Site, Flossmoor

63131

Novartis Investigative Site, St Louis

64111

Novartis Investigative Site, Kansas City

66160

Novartis Investigative Site, Kansas City

73102

Novartis Investigative Site, Oklahoma City

73104

Novartis Investigative Site, Oklahoma City

75246

Novartis Investigative Site, Dallas

78258

Novartis Investigative Site, San Antonio

80027

Novartis Investigative Site, Louisville

80907

Novartis Investigative Site, Colorado Springs

85718

Novartis Investigative Site, Tucson

89106

Novartis Investigative Site, Las Vegas

94705

Novartis Investigative Site, Berkeley

95817

Novartis Investigative Site, Sacramento

97225

Novartis Investigative Site, Portland

98034

Novartis Investigative Site, Kirkland

98122

Novartis Investigative Site, Seattle

98405

Novartis Investigative Site, Tacoma

99202

Novartis Investigative Site, Spokane

02035

Novartis Investigative Site, Foxborough

02421

Novartis Investigative Site, Lexington

02481

Novartis Investigative Site, Wellesley

07410

Novartis Investigative Site, Fair Lawn

07039

Novartis Investigative Site, Livingston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY